Discover how Marwan Fathallah is transforming DIA and hoping to revolutionize global healthcare

With an impressive career spanning 35 years in the healthcare industry, Fathallah shares his vision for the future of DIA and the evolving landscape of healthcare and diagnostics.

Liza Laws (LL): What motivated you to join DIA in 2023, and what are your primary goals as President and CEO?​

Marwan Fathallah (MF):​ I’ve been in the healthcare industry for 35 years, holding leadership roles across R&D, operations, and regulatory affairs. What drives me is the belief that we’re saving lives. DIA’s mission to accelerate innovation globally resonated deeply with me. The challenge now is to propel DIA into the next 60 years amidst a rapidly evolving healthcare ecosystem. We need to remain the neutral party that brings together regulators, innovators, and academia to drive patient-centered innovation.

LL: How do you balance the diverse responsibilities you held at Ortho Clinical Diagnostics in your current role?​

MF:​ My career has spanned the entire healthcare value chain, from innovation to patient engagement. This breadth of experience is crucial in addressing the needs of our diverse stakeholders at DIA. Understanding the global landscape, nurturing relationships, and navigating geopolitical challenges all center around the patient. This focus is what guides us at DIA.

LL: What are the most significant trends in healthcare and diagnostics today?​

MF:​ Rare diseases and advanced therapies, like oncology and ALS treatments, are at the forefront. AI is revolutionizing diagnostics and drug discovery, potentially lowering costs. Personalized medicine and gene editing are akin to a modern gold rush. The pandemic showed us the power of collaboration, with regulators now more engaged with innovators. However, the challenge remains in making these therapies scalable and affordable.

LL: What role will technological advancements play in the future of clinical diagnostics and healthcare?​

MF:​ The relationship between diagnostics and drug therapy is becoming more integrated, especially with advancements in AI. Imagine a streamlined process where a cancer diagnosis leads directly to a

personalized treatment plan. AI could bridge diagnostics and therapy, offering predictive insights and tailored interventions.

LL: Can you outline your strategic vision for DIA over the next five years?​

MF:​ Our strategic roadmap focuses on three pillars: investing in our foundation, protecting and expanding our core, and diversification. We’re enhancing our infrastructure to support growth, maintaining excellence in our core activities like conferences and education, and expanding into evolving regions like Africa, the Middle East, and India. We’re also diversifying through think tanks, consortiums, and research collaborations.

LL: How is DIA addressing post-market product science and engineering challenges?​

MF:​ Pharmacovigilance and post-market surveillance are critical. We’re raising awareness, offering training, and collaborating with regulators to define tolerability standards. These efforts ensure that safety and effectiveness are continuously monitored and improved upon.

LL: What are the key milestones you aim to achieve at DIA in the near future?​

MF:​ We have several milestones, including conferences in Latin America, the Middle East, and Asia, and partnerships with key regulatory bodies. We’ve also added Dr David Makanga from the Gates Foundation to our board, focusing on cultivating our presence in Africa. Each milestone comes with an action plan to ensure we deliver tangible results.

LL: How do you feel about this event and its progress?​

MF:​ The event has been incredibly rewarding. The regulatory convergence session, featuring top regulators from around the world, was packed. Our opening plenary and exhibition hall were bustling with activity. There’s a unique emotional connection at DIA events, driven by a shared belief in saving lives. This commitment is what sets us apart and drives our success.

Marwan Fathallah’s leadership goal is steering DIA towards a future where innovation and collaboration thrive, ensuring that the organization continues to be a cornerstone in the global healthcare ecosystem.